NOD2/CARD15 Variants Are Not a Risk Factor for Clinical Outcome after Nonmyeloablative Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 8, 2011, Pages 1231-1236

  Van der Straaten, Hanneke M ^a   Paquay, Martine M ^a   Tilanus, Marcel G J ^a   van Geloven, Nan ^b   Verdonck, Leo F ^a   Huisman, Cynthia ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

NOD2 CARD15; Nonmyeloablative allogeneic stem cell transplantation; Polymorphisms; SNP

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR; FEMALE; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; GRAFT RECIPIENT; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; RELAPSE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 79960268622     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.12.709     Document Type: Article

References (17)

1. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
2. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
3. Fishbein T., Novitskiy G., Mishra L., et al. NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 2008, 57:323-330.
4. Watanabe T., Asano N., Murray P.J., et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008, 118:545-559.
5. Strober W. The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity 2009, 31:377-388.
6. Elmaagacli A.H., Koldehoff M., Hindahl H., et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 2006, 81:247-254.
7. Granell M., Urbano-Ispizua A., Arostegui J.I., et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica 2006, 91:1372-1376.
8. Hildebrandt G.C., Granell M., Urbano-Ispizua A., et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:67-74.
9. Holler E., Rogler G., Herfarth H., et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004, 104:889-894.
10. Holler E., Rogler G., Brenmoehl J., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006, 107:4189-4193.
11. Holler E., Hahn J., Andreesen R., et al. NOD2/CARD15 polymorphisms in allogeneic stem-cell transplantation from unrelated donors: T depletion matters. J Clin Oncol 2008, 26:338-339.
12. Mayor N.P., Shaw B.E., Hughes D.A., et al. et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol 2007, 25:4262-4269.
13. Sairafi D., Uzunel M., Remberger M., Ringden O., Mattsson J. No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant 2008, 41:961-964.
14. Nguyen Y., Al-Lehibi A., Gorbe E., et al. Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. Blood 2010, 115:3625-3631.
15. Gray R. cmpprsk: Subdistribution Analysis of Competing Risks. R package version 2 2-0 2008. Available at: , http://biowww.dfci.harvard.edu/~gray.
16. van der Linde K., Boor P.P.C., Houwing-Duistermaat J.J., et al. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies. Eur J Gastroenterol Hepatol 2007, 19:449-459.
17. van der Velden W.J.F.M., Blijlevens N.M.A., Maas F.M.H.M., et al. NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. Bone Marrow Transplant 2009, 44:243-248.